Pharmaceutical competition rarely changes through a single event. A company's strategic position can shift following a clinical milestone, licensing agreement, patent development, regulatory decision, manufacturing expansion, acquisition or investment. Each event may appear isolated, but together these signals can reveal changes in pipeline strength, market positioning or commercial intent. This is why competitive intelligence has become an important component of pharmaceutical and biotech strategy. Roots Analysis (https://www.rootsanalysis.com/ ) has developed a dedicated competitive-intelligence practice covering drug discovery, R&D, commercialization, sales and marketing intelligence, primary research and ongoing monitoring. BioSignalIQ and the Move Toward Signal-Based Intelligence BioSignalIQ(https://www.rootsanalysis.com/biosignaliq ) adds a technology-enabled dimension to this intelligence model. The platform tracks company, clinical, regulatory, manufacturing, partnership and investment developments and assesses why individual developments may matter commercially. It then allows opportunities to be compared using scoring and timing.
